Nordic Bioscience receives Letter of Support from the U.S. Food and Drug Administration (FDA) for further study of the PRO-C3 biomarker assay in tumor fibrosis studies
Madrigal met both primary endpoints in the Phase 3 MAESTRO-NASH clinical trial of Resmetirom
Nordic Bioscience's landmark collaboration study on PRO-C6 in NEJM Evidence has received two editorials.
Research published in NEJM Evidence positions Nordic Bioscience’s PRO-C6 as next-generation biomarker assay for trial enrichment in HFpEF
A multi-million deal in Denmark
Counterfeit versions of Nordic Bioscience's PRO-C3 biochemical assay have recently entered circulation globally.
Nordic Bioscience and Roche Diagnostics Strengthen Collaboration for Development of Biomarkers for Chronic Diseases
We showcase how the Nordic Bioscience Protein Fingerprint neo-epitope technology provides serological quantification for Extracellular Matrix (ECM) remodeling.
Promising outlook for prognostic biomarkers related to HFpEF
KKR's investment will support Nordic Bioscience with its ambitious growth goals: Global expansion of R&D services, diagnostics platform, leading patent portfolio, and drug development.
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
